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Irinotecan (CPT-11) is a potent chemotherapeutic agent, however, its clinical usage
is often limited by the induction of severe gastrointestinal (GI) toxicity, especially
late-onset diarrhea. HuangQin Decoction (HQD), commonly used for the treatment of
GI ailments, has been proved could significantly ameliorate the intestinal toxicity of
CPT-11. To reveal the mechanisms of CPT-11-induced toxicity and the modulation
effects of HQD, a previous untargeted metabolomics study was performed and the
results indicated that HQD may protect the GI tract by altering the metabolism of
bile acids (BAs). Nevertheless, the untargeted assays are often less sensitive and/or
efficient. In order to further confirm our previous findings, here in this paper, serum and
tissues metabolic profiles of 17 BAs were analyzed using liquid chromatography-tandem
mass spectrometry based targeted metabolomics. The results indicated that serum and
tissues levels of most BAs were significantly decreased after CPT-11 administration,
except some hydrophobic BAs. Co-treatment with HQD could markedly attenuate
CPT-11-induced GI toxicity and reverse the alterations of hydrophobic BAs. Despite the
fact that the BAs pool size remained unchanged, the balance of BAs had shifted leading
to decreased toxicity after HQD treatment. The present study demonstrated for the first
time that the precise interaction between HQD, CPT-11-induced intestinal toxicity and
BAs’ homeostasis.
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INTRODUCTION
Irinotecan (CPT-11), a water-soluble derivative of camptothecin, is a highly effective
chemotherapeutic agent which has been widely used in clinical practice to treat colon (Mukai
et al., 2009), gastric (Takiuchi, 2009), pancreatic (Stathopoulos et al., 2003), and varieties of other
cancers (Mrozek et al., 2008; Otsuka et al., 2015; Trafalis et al., 2016) through the inhibition
of DNA topoisomerase I. However, dose-limiting toxicities myelosuppression, neutropenia, and
gastrointestinal (GI) toxicity, particularly severe late-onset diarrhea, compromise the efficacy and
safety of irinotecan-based chemotherapy (Kakolyris et al., 2001; Benson et al., 2004). Prophylaxis
with atropine inhibit the activity of cholinesterase to eliminate acute (early-onset) diarrhea (Yumuk
et al., 2004). However, high dose of loperamide, recommended to relieve CPT-11-induced severe
late-onset diarrhea, is non-specific and shows limited effect (Suzuki et al., 2000; Barbounis et al.,
2001; Pro et al., 2001). Find out other more effective modulator agents that either alleviate the
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toxic side effects associated with CPT-11 treatment and/or
enhance the therapeutic efficacy of the anti-tumor activity will be
of great value.
HuangQin Decoction (HQD), a traditional Chinese
formulation from Shang Han Lun of the Han Dynasty, has
been established for more than 1800 years for the treatment
of abdominal spasms, diarrhea, vomiting, and nausea, the
same symptoms commonly observed toxic effects in cancer
patients receiving chemotherapy (Sharma et al., 2005). Some
animal experiments and clinical trials have demonstrated that
PHY906 (US Patent No. 7025993), a modified pharmaceutical
preparation derived from HQD, could significantly ameliorate
chemotherapy-induced GI toxicity and intensify the therapeutic
efficacy of a number of anticancer drugs (Yen et al., 2009; Lam
et al., 2010, 2015; Saif et al., 2010, 2014; Kummar et al., 2011).
However, the underlying mechanisms that are responsible for
the modulation effects and molecular process of HQD are still
incomprehensive.
HQD is a four-herb Chinese Medicine Formula, including
Scutellaria baicalensis Georgi, Glycyrrhiza uralensis Fisch,
Paeonia lactiflora Pall, and Ziziphus jujuba Mill. The
chemical components of HQD usually act simultaneously
and synergistically on multiple targets in the body based on
holistic concepts. Metabolomics, a novel holistic approach
to study metabolic changes, is consistent with the spirit of
Traditional Chinese Medicine (TCM). Focusing on endogenous
metabolites will provide a global insight into the actions of
HQD. Previously, an untargeted metabolomics study using gas
chromatography-mass spectrometry (GC/MS) and ultra-fast
liquid chromatography coupled with ion trap time-of-flight
mass spectrometry (UFLC-IT–TOF/MS) in combination
was performed. The study demonstrated that HQD is really
a kind of effective modulators of CPT-11. Meanwhile, the
potential endogenous metabolites changes associated with
CPT-11-induced perturbations and HQD treatment were
screened out (Wang et al., 2015). In addition to the perturbations
of amino acids, lipids, and energy metabolism homeostasis, the
significantly altered bile acids (BAs) could also be considered
as potential biomarkers for the metabolic regulatory effects
of CPT-11 or HQD. Noting that changes of BAs profiles are
extensively linked to CPT-11 exposure (Kobayashi et al., 2001;
Sawano et al., 2015; Fang et al., 2016). Moreover, BAs have
been proved as sensitive biomarkers to evaluate the intestinal
function (Gnewuch et al., 2009; Wildenberg and van den Brink,
2011; Devkota et al., 2012; Zhou et al., 2014). Elucidating the
physiological function of BAs could help us understand the
mechanisms associated with toxicity and disease state. However,
the precise information on the interaction between HQD,
CPT-11-induced intestinal toxicity and BAs’ homeostasis is
lacking.
Although the altered BAs profiles in CPT-11-induced diarrhea
model have been found based on our previous metabolomics
analysis, the untargeted assays are often less sensitive and/or
efficient. In addition, the metabolites identified by database or
library search are ambiguous. Whether one of the mechanisms
of HQD’s ability in attenuating CPT-11-induced intestinal
toxicity is by restoring the homeostasis of BAs still unclear.
Thus in order to further confirm our previous findings, here
in this paper, serum and tissues metabolic profiles of 17
BAs were analyzed using liquid chromatography-tandem mass
spectrometry (LC-MS/MS)-based targeted metabolomics.
MATERIALS AND METHODS
Chemicals and Reagents
Cholic acid (CA), glycocholic acid (GCA), taurocholic acid
(TCA), chenodeoxycholic acid (CDCA), glycochenodeoxycholic
acid (GCDCA), taurochenodeoxycholic acid (TCDCA),
ursodeoxycholic acid (UDCA), glycoursodeoxycholic acid
(GUDCA), tauroursodeoxycholic acid (TUDCA), deoxycholic
acid (DCA), glycodeoxycholic acid (GDCA), taurodeoxycholic
acid (TDCA), taurolithocholic acid (TLCA), and cortisone
acetate were purchased from Sigma-Aldrich (St. Louis, MO,
USA). α-Muricholic acid (α-MCA) and tauromuricholic acid
(TMCA) were purchased from Steraloids Inc (Newport, RI,
USA). All other reagents and solvents were of high performance
liquid chromatography (HPLC) grade. Deionized water was
purified using a Milli-Q system (Millipore, Bedford, MA,
USA). S. baicalensis Georgi (Hebei Province), G. uralensis Fisch
(Inner Mongolia of China), P. lactiflora Pall (Anhui Province),
and Z. jujuba Mill (Henan Province) were authenticated by
Dr. Ehu Liu (State Key Laboratory of Natural Medicine, China
Pharmaceutical University, China).
CPT-11 and HQD Preparation
CPT-11 (Jaripharm Inc, Lianyungang, China) was obtained
as irinotecan hydrochloride. It was prepared, according to
manufacturer’s (CamptosarTM, Pfizer Inc., USA) directions and
the published papers, to duplicate the clinical formulation:
20 mg/mL CPT-11, 45 mg/mL sorbitol (Sigma, St Louis, MO,
USA), and 0.9 mg/mL lactic acid (Sigma, St Louis, MO, USA)
dissolved in deionized water and subsequently heated to 70–90◦C
until the solution turned to clear. The pH was adjusted to 3.5
using 1 M NaOH. The resulting solution was sterile-filtered and
stored protected from light until the moment of administration
(Hardman et al., 1999; Trifan et al., 2002; Yang et al., 2006).
HQD was prepared by decocting S. baicalensis Georgi,
G. uralensis Fisch, P. lactiflora Pall, and Z. jujuba Mill at ratio of
3:2:2:2 by dry weight. The filtrate was collected then concentrated
as a decoction of 1 g/mL crude drug, stored in the refrigerator
before intragastric administration to rats.
Animal Experiments and Sample
Collection
Male Sprague-Dawley rats (Sino-British SIPPR/BK Lab Animal
Ltd., Shanghai, China) initially weighing 200 ± 20 g were used
in present study. Animals were housed in a routine laboratory
conditions with a temperature-controlled (25◦C) environment
and a 12 h dark/light cycle throughout the acclimatization
and experimental periods. The experimental protocols were in
accordance to the Guide for the Care and Use of Laboratory
Animals and approved by the Animal Ethics Committee of China
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Pharmaceutical University (License Number: SYXK 2012-0035).
After 1 week adaptation, rats were randomly divided into three
groups either received vehicle alone, CPT-11 alone, or CPT-11
and HQD. The toxicity model was constructed by treatment
of animals with CPT-11 at 150 mg/kg by intravenous injection
(i.v.) once a day for two consecutive days (Trifan et al., 2002).
Animals in control group injected with the same dose of vehicle.
HQD was given orally twice a day from 1 day before the start
of CPT-11 injection (day 1) for six consecutive days at a dose of
10 g/kg. While animals in control and CPT-11 group received
equivalent Milli-Q water. All the gavage were 30 min prior to
the dosing of CPT-11 on days 1 and 2. The mortality, weight
loss, and food intake of animals were monitored daily. Scoring
of diarrhea was conducted twice daily (8 a.m. and 8 p.m.). The
severity of delayed diarrhea was scored as described by Kurita
et al. (2000).
Diarrhea observed immediately (occur within 2 h) after
the dosing of CPT-11 and approximately 48 h after the final
administration were considered to be acute diarrhea and late-
onset diarrhea, respectively. Serum and tissues (liver, jejunum,
ileum, cecum, colon, and rectum) were collected on day 5,
the most severe day of late-onset diarrhea. After coagulation
(1 h) and centrifugation (8,000 rpm for 10 min), serum samples
were aliquoted and then stored at −80◦C until needed for
preparation and analysis. Some tissue samples were used for
histological examination and others were used for quantitative
analysis. The scheme of the whole experiment is shown in
Figure 1.
Histopathology Examination
Tissue sections (liver, jejunum, ileum, cecum, and colon) were
dissected on the most severe day of late-onset diarrhea (day 5),
fixed in 10% neutral formalin and stained with hematoxylin–
eosin. The routine histopathology assessment was performed in
a blinded manner.
Quantification of Bile Acids in Biological
Samples
Metabolomic profiling of different classes of BAs in biological
samples was assayed by a LC-MS/MS-validated method. Serum
samples were thawed at room temperature. A total of 200 µL
methanol and 10 µL cortisone acetate [internal standard (IS),
100 µg/mL] were added to 50 µL serum and the mixture was
vortexed for 5 min. After centrifuged twice at 16,000 rpm (4◦C)
for 10 min, the supernatant was used for LC-MS/MS analysis.
Approximately 100–150 mg tissue samples, including liver and
intestines, were homogenized in 10 volumes of methanol. After
10 min of centrifugation (16,000 rpm, 4◦C), 50 µL supernatant
was spiked with 10 µL IS and 150 µL methanol, vortexed,
centrifuged, and then used for further analysis. The separation
was finally carried out on a ZORBAX Eclipse XDB-C18
(2.1 × 150 mm, 3.5 µm) (Agilent Technologies). The mobile
phase consisted of (A) acetonitrile and (B) 0.1% formic acid.
The gradient elution started with 25% A for 20 min, linearly
increased to 60% B in 65 min and brought back to 25% A in 5 min
followed by 10 min of re-equilibration. The mass spectrometry
(MS) analysis was performed in a triple quadruple TSQ Quantum
mass spectrometer via electrospray ionization (ESI) interface
(Thermo Fisher, Palo Alto, CA, USA). The parameters were as
follows: ESI (−), spray voltage, 3.8 kV; capillary temperature,
380◦C; scan width for multiple-reaction monitoring (MRM), 0.1
m/z. Nitrogen was used as sheath (40 arb) and auxiliary (25 arb)
gas. Argon was used as the collision gas (1.0 mTorr). BAs with no
reference (β-MCA and ω-MCA) were semi-quantified by using
calibration curve of homologous standards (α-MCA). The main
parameters for MS/MS detection of BAs as well as the internal
standard cortisone acetate are summarized in Table 1.
Method Validation
The method used in this study was developed in terms
of linearity, accuracy, precision, extraction recovery, matrix
effects, and stability following the compliance criteria described
by Food and Drug Administration (FDA) guidance for
Bioanalytical Method Validation. Charcoal-treated serum and
tissues homogenates were served as biological matrices for the
preparation of standards and quality control (QC) samples.
Calibration curves were constructed by plotting the peak–
area ratio of each BA to IS versus the concentrations
of the BA in each corresponding matrix. Intraday and
interday accuracy and precision were determined using 3QC
concentrations distributed throughout the calibration range
for each analyte. Extraction recoveries only took into account
the efficiency of the extraction procedure. Matrix effects were
determined by adding the analytes to each blank matrix after
extraction and compared with the same amount of analytes
in pure solvents. The freeze–thaw, short-term, long-term, and
post-preparative stability of the BAs were also investigated in
current method.
Data Processing and Statistical Analysis
All the results are present as mean ± standard deviation (SD).
The multivariate data analysis, principal component analysis
(PCA) and partial least squares discriminant analysis (PLS-DA),
were conducted by SIMCA-P (version 13.0, Umetrics, Sweden).
Statistical evaluations were performed using non-parametric
Mann–Whitney U-test (SPSS Inc., Chicago, USA). Differences
were considered the results with P-values <0.05.
RESULTS
Method Validation
A fully validated method is appropriate for all the determinations.
The accuracy ranges from 86.85 to 111.81% in all tested
samples. Precision, measured as coefficient of variation (CV),
was below 14.37 and 13.30% for intraday and interday for all
BAs, respectively. In terms of linearity, the regression coefficients
for all the calibration curves of BAs were higher than 0.99.
Extraction recoveries at all QC concentrations were >83.42% in
serum,>71.79% in liver, and>78.46% in intestine. No significant
matrix effects for BAs were observed. In addition, stability studies
indicated that BAs were stable in serum and tissues for at least
8 h at room temperature, at least three freeze–thaw cycles, in the
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FIGURE 1 | Experimental design. Animals either received vehicle alone, CPT-11 alone, or CPT-11 and HQD. The toxicity model was constructed by treatment of
animals with CPT-11 at 150 mg/kg by intravenous injection (i.v.) once a day for two consecutive days (day 1–2). HQD (10 g/kg) was given orally twice a day for 6
days beginning on day 0 (day 0–5). The mortality, weight loss and food intake of animals were monitored daily. The rats were finally euthanized on day 5. Serum and
tissues (liver, jejunum, ileum, cecum, colon, and rectum) were collected for preparation and analysis. The dashed part is completed in the pilot study.
−80◦C for 2 weeks, and also in the reconstitution solution at 16◦C
for 12 h.
Histology Analysis
As anticipated, marked intestinal pathological changes were
observed in rats received CPT-11 alone, including epithelial
degeneration, villus shortening, gland atrophy, inflammatory
cellular infiltration, and submucosal edema. The histologic
lesions were extremely severe in ileum, followed by cecum,
and minimal in jejunum and colon. Conversely, liver histology
appeared normal. These intestinal damages were significantly
alleviated in rats co-treated with HQD (Figure 2). Histological
sections verified that the CPT-11-induced toxicity model was
successfully produced in present study and co-treatment with
HQD effectively ameliorated the intestinal damages induced by
CPT-11.
HQD Attenuated the Body Weight Loss
and Late-Onset Diarrhea Induced by
CPT-11
Rats repeated dosing CPT-11 (150 mg/kg/day i.v.) for two
consecutive days appeared serious anorexia and rapid decrease
in body weight, reached 85.57 ± 2.20% of initial body weight
by day 5. However, rats co-administered with HQD significantly
attenuated body weight loss (91.49 ± 2.54% by day 5) and
had a higher food intake level as compared with rats only
received CPT-11. In addition, severe acute (occurred within 2 h
after CPT-11 injection on days 1–2) and late-onset (chronically
present during days 4–5) diarrhea were observed in rats treated
with CPT-11 alone. Rats co-administered with HQD significantly
improved the late-onset diarrhea induced by CPT-11, but failed
to prevent the acute diarrhea on days 1 and 2. As expected, rats
received the vehicle alone did not show any significant signs of
toxicity. None of the rats died during the experiment (Table 2).
Targeted Quantitation Revealed Altered
Bile Acids Profiles in Multiple
Compartments of Rats after CPT-11
Treatment
To targeted assay of BAs profiles throughout the enterohepatic
system, concentrations of 17 individual BAs, including seven free
BAs, six taurine-conjugated BAs, and four glycine-conjugated
BAs were simultaneously determined and quantified in
biological samples using a sensitive high-throughput LC-MS/MS
(Supplementary Figure 1). A previously uncharacterized
compartment-specific dysregulation feature of BAs was identified
in different groups of rats. CPT-11-treated animals showed very
different profiles from controls, with a marked reduction of
CA, TCA, α-MCA, TMCA, UDCA, and TUDCA in serum.
Levels of TCA and TUDCA were also decreased in liver and
certain intestinal segments. Additionally, β-MCA was increased
in liver and colon, while its conjugate—TMCA, was decreased
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TABLE 1 | Structures of unconjugated, glycine- and taurine-conjugated bile acids and their optimum MS–MS parameters.
Bile acid R1 R2 R3 R4 [M-H]− MRM transitions CE(V)
α-MCA OH (β) OH(α) H OH 407.2 407.2→ 407.2 20
β-MCA OH (β) OH (β) H OH 407.2 407.2→ 407.2 20
ω-MCA OH (α) OH (β) H OH 407.2 407.2→ 407.2 20
CA H OH (α) OH OH 407.2 407.2→ 407.2 20
CDCA H OH (α) H OH 391.2 391.2→ 391.2 20
DCA H H OH OH 391.2 391.2→ 391.2 20
UDCA H OH (β) H OH 391.2 391.2→ 391.2 20
GCA H OH (α) OH NHCH2CO2H 464.2 464.2→ 74.0 40
GCDCA H OH (α) H NHCH2CO2H 448.2 448.2→ 74.0 40
GDCA H H OH NHCH2CO2H 448.2 448.2→ 74.0 40
GUDCA H OH (β) H NHCH2CO2H 448.2 448.2→ 74.0 40
TMCA OH (α) OH (α) H NHCH2CH2SO3H 514.2 514.2→ 80.0 70
TCA H OH (α) OH NHCH2CH2SO3H 514.2 514.2→ 80.0 70
TCDCA H OH (α) H NHCH2CH2SO3H 498.2 498.2→ 80.0 70
TDCA H H OH NHCH2CH2SO3H 498.2 498.2→ 80.0 70
TUDCA H OH (β) H NHCH2CH2SO3H 498.2 498.2→ 80.0 70
TLCA H H H NHCH2CH2SO3H 482.2 482.2→ 80.0 70
IS 401.2 401.2→ 340.5 40
Backbone and side chain structures of the major BAs. CE: collision energy; IS (internal standard): cortisone acetate.
in ileum, colon, and rectum. Notably, the levels of hydrophobic
BAs—CDCA, GCDCA, TCDCA, especially DCA, GDCA,
TDCA, and TLCA were significantly increased in almost all
of the tested tissues. Contrary to what we expected, the most
obvious disturbance of BAs homeostasis was shown in serum
rather than in target organs, such as liver and intestine. This
may be because circulating BAs comprehensively reflected
the hepatic input and intestinal reabsorption (Supplementary
Table 1). Meanwhile, as shown in PCA and PLS-DA score
plots, the CPT-11-treated group serum and tissues could be
clearly distinguishable from the control group (Figure 3 and
Supplementary Figure 2).
HQD Shifted the Balance of Bile Acids
Leading to Decreased Toxicity
Compared with only CPT-11-treated animals, HQD
co-treatment could partly restore the homeostasis of BAs.
Although there were some overlaps among three groups
in PCA score plots (Supplementary Figure 2), the control
group, CPT-11-treated group, and HQD co-treated group were
separately clustered and could be clearly distinguished in rat
serum and tissues based on PLS-DA model (Figure 3). The
quantitative results showed that HQD mainly regulated the
hydrophobic BAs (Figure 4). Hydrophobicity is an important
determinant of the biological activity exhibited by BAs (Powell
et al., 2001). Although the levels of cytoprotective UDCA and
its conjugates remained unchanged, that of cytotoxic BAs,
including CDCA, GCDCA, TCDCA, DCA, GDCA, TDCA,
and TLCA, were markedly decreased in multiple compartments
of rats received HQD. In fact, both CPT-11-treated and HQD
co-treated rats had a slightly altered BAs pool sizes in serum
and tissues. However, there was no statistically significant
difference in BAs pool size between CPT-11 group and HQD
group (Supplementary Figure 3). These data may reflect the fact
that HQD was more likely to shift the balance of BAs rather
than influence the BAs pool size. Meanwhile, it also suggested
that, in addition to total BAs concentration, the composition of
BAs is more important regarding BAs-related functions in the
body. The profound remodeling of the BAs composition may
be one of the mechanisms of HQD to reduce the toxicity of
CPT-11.
DISCUSSION
BAs, the end products of cholesterol metabolism, are major
components of bile. They are synthesized exclusively in the
liver and further delivered to the intestinal tract, where they
are metabolized by the gut microbiota into the secondary BAs.
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FIGURE 2 | CPT-11-induced intestinal damage. Tissue sections (liver, jejunum, ileum, cecum, and colon) were dissected for routine histopathology assessment.
Representative photographs of histological examination for (A–E) control, (F–J) model, and (K–O) HQD group. Bar = 50 µm.
In addition to digesting and absorbing of lipids, BAs are also
important signaling molecules that are involved in regulation
of various metabolic processes via activation of some specific
nuclear receptors and G protein-coupled receptor (Nguyen and
Bouscarel, 2008; Prakash and Gorfe, 2013; de Aguiar Vallim et al.,
2013; Legendre et al., 2014; Qi et al., 2015). Researches suggested
BAs are closely related to intestinal dysbiosis. Thus, elucidating
the function of BAs could facilitate our understanding of the
mechanisms associated with disease state. To our knowledge, this
is the first study that focused on the precise interaction between
HQD, CPT-11-induced intestinal toxicity, and BAs’ homeostasis
(Figure 5).
Multiple factors contribute to the abnormal composition or
delivery of BAs. For example, gastrointestine injury hampers the
efficient absorption of BAs and thus influences the enterohepatic
TABLE 2 | Relative body weight and average diarrhea score of animals.
Treatment group Diarrhea score,
mean% ± SD
Relative body weight,
mean% ± SD
Control 0.00 ± 0.00 103.35 ± 2.10
CPT-11 2.19 ± 0.99∗∗ 85.57 ± 2.20∗∗∗
CPT-11 + HQD 1.38 ± 0.69# 91.49 ± 2.54###
Relative body weight was calculated relative to animals’ weight at the beginning of
the experiment (day 0). Significance compared with control group: ∗∗∗P < 0.001,
∗∗P < 0.01. Significance compared with model group: ###P < 0.001, #P < 0.05
(Mann–Whitney U-test).
circulation of BAs. Disturbed intestinal microbiota results in
quantitative and qualitative BAs changes. In fact, CPT-11
not only induce intestinal damage, but also disrupt intestinal
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FIGURE 3 | PLS-DA models of bile acids profiles. Based on the score plots, bile acids profiles of three groups of rats were shown for (A) serum, (B) liver, (C)
jejunum, (D) ileum, (E) cecum, (F) colon, and (G) rectum. (A) R2X = 0.614, R2Y = 0.806, Q2 = 0.641; (B) R2X = 0.710, R2Y = 0.753, Q2 = 0.575; (C) R2X = 0.530,
R2Y = 0.647, Q2 = 0.483; (D) R2X = 0.513, R2Y = 0.830, Q2 = 0.524; (E) R2X = 0.471, R2Y = 0.709, Q2 = 0.547; (F) R2X = 0.614, R2Y = 0.753, Q2 = 0.540;
(G) R2X = 0.711, R2Y = 0.875, Q2 = 0.612.
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FIGURE 4 | Concentrations of hydrophobic bile acids in biological samples among different groups. Graphics represent the mean ± SD. P-values were
determined by Mann–Whitney U-test. Significance compared with control group: ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05. Significance compared with model group
(only CPT-11-treated group): ###P < 0.001, ##P < 0.01, #P < 0.05.
microbiota (Stringer et al., 2008). Targeted quantitation revealed
that CPT-11-treated rats had very different profiles from
controls, accompanying with a significantly elevation of CDCA,
DCA, and their glycine or taurine conjugates. However, high
levels of BAs in lumen, especially those hydrophobic BAs,
probably induce or aggravate intestinal damage. Numerous
studies have demonstrated that hydrophobic BAs can induce
membrane perturbation, disrupt membrane integrity, and release
intracellular constituents (Rodrigues et al., 1999; Im and
Martinez, 2004; Akare and Martinez, 2005). Fukumoto et al.
(1999) have reported that elevation of TDCA, TCDCA, and
their unconjugated BAs in serum could enhance gastric mucosal
damage and this effect was directly attributed to the cytotoxicity
of these BAs. Besides, DCA and these relevant hydrophobic
BAs can activate nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) signaling cascade to induce the
production of pro-inflammatory molecules (such as interleukin
(IL)-1, IL-8, and tumor necrosis factor-alpha (TNF-α); Miyake
et al., 2000; Muhlbauer et al., 2004) and aggravate IL-10
reduction caused by CPT-11 in CD4+ T cells (Fang et al.,
2016). These reports just support the potential roles of toxic
BAs in potentiating the pathological development of mucositis.
Moreover, luminal concentrations of BAs are known to exert a
cathartic effect by altering salt and water transport (Chadwick
et al., 1979; Camilleri et al., 1980; Snape et al., 1980), affecting
the expression of various aquaporin water channels (Yde et al.,
2016) and stimulating intestinal motility (Alemi et al., 2013).
In combination, these effects may contribute to at least certain
aspects that patients treated with CPT-11 always suffer from
severe late diarrhea.
Co-treatment with HQD could markedly attenuate
CPT-11-induced GI toxicity and reverse the alterations of
BAs. Despite the fact that BAs pool size and cytoprotective BAs
(UDCA, GUDCA, and TUDCA) remained unchanged, it was
of interest to note that multiple unconjugated and conjugated
hydrophobic BAs were significantly decreased in serum and
tissues of rats upon HQD treatment. Besides, the global BAs
metabolic profiles in HQD group was more similar to normal
control group. Although the mechanisms behind why HQD
could regulate the BAs metabolism homeostasis were not solved
in this paper, it has been reported that the bioactive constituents
of HQD can directly interfere with the normal metabolism
of BAs. For example, some natural flavonoids like baicalein
and chrysin in S. baicalensis were demonstrated to be the
pregnane X receptor (PXR) ligands (Dou et al., 2012, 2013).
Glycyrrhizic acid, the main active ingredient of G. uralensis,
can activates farnesoid X receptor (FXR) (Distrutti et al., 2015).
Both PXR and FXR can control BAs homeostasis (Modica
et al., 2009). Liquiritigenin, an active component of licorice,
functions as inducer to increase the protein and mRNA levels of
multidrug resistant protein 2 and bile salt export pump and thus
influences the transport of BAs (Kim et al., 2009). P. lactiflora
can also change the serum profiles of BAs by certain unknown
mechanisms (Wang et al., 2012). What’s more, most TCM
formulas exert multi-targeting actions including the modulation
of smooth muscle motility in the GI tract and restoration of
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FIGURE 5 | The impact of CPT-11 and HQD on bile acids metabolome. The bile acids profile in the intestine shows the combined data from five segments
(jejunum, ileum, cecum, colon, and rectum). Bile acids with arrow is significantly changed (↑ content increased; ↓ content decreased).
intestinal flora (Xiao et al., 2015). Since there are strong and
bidirectional interactions between gut microbiome and BAs:
microbiota affect the metabolism and function of BAs, while
BAs control microbiota overgrowth and protect intestine by
their antimicrobial activity (Swann et al., 2011; Sayin et al., 2013;
Li and Chiang, 2014). Thus, we speculated that the ability of
HQD to restore the homeostasis of BAs may also be linked to its
ability to protect the homeostasis of microbiome. These different
mechanisms are likely to act synergistically in regulating BAs
metabolism Homeostasis.
CONCLUSION
In the present study, LC-MS/MS based targeted metabolomics
revealed for the first time that the effects of CPT-11-induced
intestinal toxicity and HQD’s ability on rat enterohepatic BAs.
Compared with total or selected individual BAs level, a whole
profile of BAs subspecies may more sensitively reflect the
information about intestinal malfunction. Tissues and serum
levels of most BAs were significantly decreased after CPT-11
administration, except some hydrophobic BAs. Co-treatment
with HQD could markedly attenuate CPT-11-induced GI toxicity
and reverse the alterations of BAs. Despite that there was
no change in total BAs levels compared with model group,
the balance of BAs had shifted leading to decreased toxicity
after HQD treatment. Although the mechanisms behind why
specific BA was elevate or decreased in diarrhea rats and
why HQD could improve the BAs metabolism homeostasis were
not solved in this paper, the value of further research was
emphasized.
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